Latest News - Fillers & Injectables

Wednesday, August 09, 2017 | PracticalDermatology.com, Product Launches and Updates, Research and Publications

Bonti’s Novel Gateway Neuromodulator Performs Well in Phase 2A Study

Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profi…

Read the full story

Wednesday, July 12, 2017 | Personnel/Company News, PracticalDermatology.com, Allergan

Allergan CEO: Consensus Needed on Medical Aesthetic Treatment in Minors

Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a ne…

Read the full story

Tuesday, June 27, 2017 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Research and Publications, American Society for Dermatologic Surgery

ASDS: Percentage of Us Wanting Cosmetic Surgery Doubled Since 2013

Nearly 70 percent of consumers now say they are thinking about getting a cosmetic treatment, according to survey data released by the American Society for Dermatologic Surgery (ASDS). The ASDS Cons…

Read the full story

Monday, June 26, 2017 | PracticalDermatology.com

Thumbs Down for Neothetics, Inc.’s LIPO-202; Stock Plummets

Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-c…

Read the full story

Tuesday, May 30, 2017 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, American Society for Dermatologic Surgery

ASDS: Nearly 10.5 Million Treatments Performed in 2016

Dermatologic surgeons performed nearly 10.5 million medically necessary and cosmetic procedures in 2016 -- five percent more than 2015 and up 31 percent since 2012, according to the 2016 American So…

Read the full story

Thursday, April 06, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Galderma

Phase 4 Studies of Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit

Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that…

Read the full story

Monday, March 20, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Allergan

FDA Approved Juvéderm Vollure XC for Correction of Facial Wrinkles and Folds

The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US piv…

Read the full story

Tuesday, March 14, 2017 | PracticalDermatology.com, Allergan

Survey Findings: Submental Region Major Pain Point for Patients

Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc. …

Read the full story

Thursday, March 02, 2017 | PracticalDermatology.com, Product Launches and Updates, Galderma

Galderma Moves to Differentiate Their Two New HA Fillers From The Fray

With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne  --stand o…

Read the full story

Thursday, February 16, 2017 | Business of Medicine, Healthcare Trends, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com

Deadline Extended for Medical Spa State of the Industry Statistical Study

The American Med Spa Association (AmSpa) has extended the deadline for the 2017 Medical Spa State of the Industry Report, administered by MarketData Enterprises and sponsored by Modern …

Read the full story

Wednesday, February 01, 2017 | Healthcare Trends, Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Research and Publications

Medical Spa State of the Industry Statistical Study Now Open

During the past five years, the medical spa industry has grown and evolved to a point where it has become one of the most exciting and lucrative new industries in the country. Because of this, it is n…

Read the full story

Monday, January 23, 2017 | PracticalDermatology.com, Product Launches and Updates, Merz

Radiesse Hits Double Digits

Merz Aesthetics’ flagship brand, Radiesse, turned 10 this year, and was feted in style at a throw-back Thursday media event in New York City. The party took beauty bloggers and journos back t…

Read the full story

Wednesday, January 04, 2017 | PracticalDermatology.com, Product Launches and Updates, Research and Publications

Revance Starts Phase III Program for Injectable Toxin in Frown Lines

Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in …

Read the full story

Tuesday, December 20, 2016 | Acquisitions and Mergers, PracticalDermatology.com, Allergan

With LifeCell Acquisition, Allergan Enters Regenerative Medicine Realm

Allergan plc has acquired the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments, Allergan reports. This acquisition combines LifeCell's products …

Read the full story

Monday, December 12, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Galderma

Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”

The FDA  approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21 -- Galderma's Restylane Refyne and Restylane Defyne…

Read the full story
Load More